Claus Meyer
YOU?
Author Swipe
View article: Protocol for CRISPR-Cas9-mediated induction of KMT2A rearrangements in cell line and umbilical cord blood hematopoietic stem and progenitor cells
Protocol for CRISPR-Cas9-mediated induction of KMT2A rearrangements in cell line and umbilical cord blood hematopoietic stem and progenitor cells Open
KMT2A rearrangements are associated with a poor clinical outcome in infant, pediatric, and adult acute lymphoblastic and myeloid leukemia. Here, we present a protocol to reconstruct chromosomal translocations with different partner genes o…
View article: Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients Open
View article: Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia Open
In adult ALL, 5-10% of patients show KMT2A translocations (KMT2A rearrangements) with only a few secondary alterations, implicating it as a leukemia-initiating factor [1,2].Approximately 95% of all fusions in adult ALL are KMT2A::AFF1 or K…
View article: Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study Open
Measurable residual disease (MRD) monitoring in childhood acute myeloid leukemia (AML) is used to assess response to treatment and for early detection of imminent relapse. In childhood AML, MRD is typically evaluated using flow cytometry, …
View article: Genetic alterations and MRD refine risk assessment for <i>KMT2A</i>-rearranged B-cell precursor ALL in adults: a GRAALL study
Genetic alterations and MRD refine risk assessment for <i>KMT2A</i>-rearranged B-cell precursor ALL in adults: a GRAALL study Open
KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is widely recognized as a high-risk leukemia in both children and adults. However, there is a paucity of data on adults treated in recent protocols, and the…
View article: P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL
P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL Open
Topic: 1. Acute lymphoblastic leukemia - Biology & Translational Research Background: B-cell acute lymphoblastic leukaemia (B-ALL) with a rearrangement involving KMT2A/MLL (KMT2A-r) accounts for 80% of infant B-ALL and 10% of adult cases. …
View article: P337: IKZF1 DELETIONS IN B-ALL: FROM ITS GENETIC BASIS TO DIAGNOSTIC ENHANCEMENT
P337: IKZF1 DELETIONS IN B-ALL: FROM ITS GENETIC BASIS TO DIAGNOSTIC ENHANCEMENT Open
Background:IKZF1 deletions are associated with an increased risk of relapse in patients with B-cell precursor acute lymphoblastic leukemia (B-ALL), and their accurate detection has great clinical impact. Aims: We illustrate the recombinati…
View article: A human genome editing-based MLL-AF4 acute lymphoblastic leukemia model recapitulates key cellular and molecular leukemogenic features. (Processed data)
A human genome editing-based MLL-AF4 acute lymphoblastic leukemia model recapitulates key cellular and molecular leukemogenic features. (Processed data) Open
The prognosis of infant B-cell acute lymphoblastic leukemia (iB-ALL) remains dismal, especially in patients harboring the MLL-AF4 (KTM2A-AFF1) rearrangement, which arises prenatally in early hematopoietic stem/progenitor cells (HSPCs) and …
View article: A human genome editing-based MLL-AF4 acute lymphoblastic leukemia model recapitulates key cellular and molecular leukemogenic features. (Processed data)
A human genome editing-based MLL-AF4 acute lymphoblastic leukemia model recapitulates key cellular and molecular leukemogenic features. (Processed data) Open
The prognosis of infant B-cell acute lymphoblastic leukemia (iB-ALL) remains dismal, especially in patients harboring the MLL-AF4 (KTM2A-AFF1) rearrangement, which arises prenatally in early hematopoietic stem/progenitor cells (HSPCs) and …
View article: Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia
Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia Open
Pediatric acute myeloid leukemia (AML) is a highly heterogeneous disease making standardized measurable residual disease (MRD) assessment challenging. Currently, patient-specific DNA-based assays are only rarely applied for MRD assessment …
View article: The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome
The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome Open
View article: The KMT2A recombinome of acute leukemias in 2023
The KMT2A recombinome of acute leukemias in 2023 Open
View article: Data from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia
Data from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia Open
Mixed lineage leukemia (MLL) gene rearrangements characterize approximately 70% of infant and 10% of adult and therapy-related leukemia. Conventional clinical diagnostics, including cytogenetics and fluorescence in situ hybri…
View article: Figure S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia
Figure S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia Open
Expression of the exon 10 fusion transcript in patient 17 and patient 32. Standard curve was established using patient 32 sample in a range from 25ng/µl to 0.1 ng/µl in 1 in 2 serial dilutions.
View article: Data from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia
Data from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia Open
Mixed lineage leukemia (MLL) gene rearrangements characterize approximately 70% of infant and 10% of adult and therapy-related leukemia. Conventional clinical diagnostics, including cytogenetics and fluorescence in situ hybri…
View article: Figure S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia
Figure S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia Open
Expression of the exon 10 fusion transcript in patient 17 and patient 32. Standard curve was established using patient 32 sample in a range from 25ng/µl to 0.1 ng/µl in 1 in 2 serial dilutions.
View article: Table S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia
Table S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia Open
Comparison of MLL fusions detected by cytogenetics, fluorescent in situ hybridization (FISH), Long distance Inverse polymerase chain reaction (LDI-PCR) and Anchored multiplex PCR enrichment (AMP-E).
View article: Table S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia
Table S1 from Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia Open
Comparison of MLL fusions detected by cytogenetics, fluorescent in situ hybridization (FISH), Long distance Inverse polymerase chain reaction (LDI-PCR) and Anchored multiplex PCR enrichment (AMP-E).
View article: Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia
Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia Open
This file contains Supplementary Methods describing the Pediatric Preclinical Testing Program (PPTP) scoring method. Supplementary Figure S1: Engraftment rates and organ infiltration of MLL-ALL xenografts. Supplementary Figure S2: Comparis…
View article: Data from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia
Data from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia Open
Purpose: Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant MLL-ALL) experience short…
View article: Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia
Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia Open
This file contains Supplementary Methods describing the Pediatric Preclinical Testing Program (PPTP) scoring method. Supplementary Figure S1: Engraftment rates and organ infiltration of MLL-ALL xenografts. Supplementary Figure S2: Comparis…
View article: Data from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia
Data from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia Open
Purpose: Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant MLL-ALL) experience short…
View article: The recombinome of IKZF1 deletions in B-ALL
The recombinome of IKZF1 deletions in B-ALL Open
IKZF1 deletions are associated with an increased risk of relapse in B-cell precursor acute lymphoblastic leukemia (B-ALL), and their accurate detection has great clinical impact. Here, we included four international cohorts of pediatric an…
View article: Molecular Characterization of 34 Children with Acute Leukemia and MLL gene Rearrangements in Argentina
Molecular Characterization of 34 Children with Acute Leukemia and MLL gene Rearrangements in Argentina Open
Infantile hemangioma (IH) is represented by proliferation of endothelium pathological vessels in infants. This tumor occurs in 5-10% of children of the first life. Frequent localization on the skin is the area of the head and neck. IH is c…
View article: 1500P Radiochemotherapy with gemcitabine as a radiosensitizer in patients with soft tissue sarcomas
1500P Radiochemotherapy with gemcitabine as a radiosensitizer in patients with soft tissue sarcomas Open
View article: Epigenetic regulator genes direct lineage switching in <i>MLL/AF4</i> leukemia
Epigenetic regulator genes direct lineage switching in <i>MLL/AF4</i> leukemia Open
The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with a lineage switch from acute lymphoblastic to acute myeloid leukemia, resulting in poor clinical outcomes caused by re…
View article: The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia Open
View article: Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias Open
The KMT2A ( MLL ) gene rearrangements ( KMT2A -r) are associated with a diverse spectrum of acute leukemias. Although most KMT2A -r are restricted to nine partner genes, we have recently revealed that KMT2A - USP2 fusions are often missed …
View article: The Immune Checkpoint ICOSLG is a Relapse-Predicting Biomarker and Therapeutic Target in Infant t(4;11) Acute Lymphoblastic Leukemia
The Immune Checkpoint ICOSLG is a Relapse-Predicting Biomarker and Therapeutic Target in Infant t(4;11) Acute Lymphoblastic Leukemia Open
View article: <i>KMT2A-CBL</i>rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
<i>KMT2A-CBL</i>rearrangements in acute leukemias: clinical characteristics and genetic breakpoints Open